METAVIA INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
METAVIA INC. (MTVA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$113.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-06
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $4.00K.
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$117.00K.
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was -$31.00K.
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was $53.00K.
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was -$297.00K.
- METAVIA INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$2.96M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$113.00K 10-Q · filed 2026-08-06 | -$144.00K derived: sum of 3 quarters · filed 2026-08-06 | -$91.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$117.00K 10-Q · filed 2026-05-14 | -$148.00K derived: sum of 2 quarters · filed 2026-08-06 | -$95.00K derived: sum of 3 quarters · filed 2026-08-06 | -$255.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$31.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | $22.00K derived: sum of 2 quarters · filed 2026-08-06 | -$138.00K derived: sum of 3 quarters · filed 2026-08-06 | -$225.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$107.00K derived: sum of 2 quarters · filed 2025-11-06 | -$194.00K 10-Q · filed 2025-11-06 | -$397.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-06-30 | -$160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$247.00K 10-Q · filed 2025-08-07 | -$450.00K derived: sum of 3 quarters · filed 2026-03-26 | -$747.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2025-03-31 | -$87.00K 10-Q · filed 2025-05-14 | -$290.00K derived: sum of 2 quarters · filed 2026-03-26 | -$587.00K derived: sum of 3 quarters · filed 2026-03-26 | -$454.00K derived: sum of 4 quarters · filed 2026-03-26 |
| 2024-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$500.00K derived: sum of 2 quarters · filed 2026-03-26 | -$367.00K derived: sum of 3 quarters · filed 2026-03-26 | -$297.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | -$297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$164.00K derived: sum of 2 quarters · filed 2025-11-06 | -$94.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $203.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $70.00K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$2.96M 10-K · filed 2025-03-20 | |||
| 2016-09-30 | -$243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$828.00K derived: sum of 2 quarters · filed 2017-11-13 | -$850.00K 10-Q · filed 2017-11-13 | |
| 2016-06-30 | -$585.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$607.00K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | -$22.00K 10-Q · filed 2017-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |